Show simple item record

dc.contributor.authorRoche, Nicolas
dc.contributor.authorColice, Gene
dc.contributor.authorIsrael, Elliot
dc.contributor.authorMartin, Richard J.
dc.contributor.authorDorinsky, Paul M.
dc.contributor.authorPostma, Dirkje S.
dc.contributor.authorGuilbert, Theresa W.
dc.contributor.authorGrigg, Jonathan
dc.contributor.authorvan Aalderen, Willem M. C.
dc.contributor.authorBarion, Francesca
dc.contributor.authorHillyer, Elizabeth V.
dc.contributor.authorThomas, Victoria
dc.contributor.authorBurden, Anne
dc.contributor.authorBrett McQueen, R.
dc.contributor.authorPrice, David B.
dc.date.accessioned2017-12-06T17:46:32Z
dc.date.available2017-12-06T17:46:32Z
dc.date.issued2016-06
dc.identifier.citationRoche , N , Colice , G , Israel , E , Martin , R J , Dorinsky , P M , Postma , D S , Guilbert , T W , Grigg , J , van Aalderen , W M C , Barion , F , Hillyer , E V , Thomas , V , Burden , A , Brett McQueen , R & Price , D B 2016 , ' Cost-Effectiveness of Asthma Step-Up Therapy as an Increased Dose of Extrafine-Particle Inhaled Corticosteroid or Add-On Long-Acting Beta2-Agonist ' Pulmonary Therapy , vol. 2 , no. 1 , pp. 73-89 . https://doi.org/10.1007/s41030-016-0014-2en
dc.identifier.issn2364-1746
dc.identifier.otherPURE: 112728832
dc.identifier.otherPURE UUID: 6a5aad14-f6e1-43de-97ec-49e1352c08eb
dc.identifier.otherRIS: urn:5C182CA0B25EBF20F545C0FF82C5F1EA
dc.identifier.otherRIS: Roche2016
dc.identifier.urihttp://hdl.handle.net/2164/9733
dc.descriptionThe analyses were funded by an unrestricted grant from Teva Pharmaceuticals Limited of Petach Tikva, Israel. Access to data from the Optimum Patient Care Research Database was co-funded by Research in Real-Life Ltd (RiRL), Cambridge, UK. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. The authors thank Julie von Ziegenweidt for assistance with data extraction.en
dc.format.extent17en
dc.language.isoeng
dc.relation.ispartofPulmonary Therapyen
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.subjectasthmaen
dc.subjectBeclometasone dipropionate hydrofluoroalkaneen
dc.subjectBudesonide/formoterol fumarate dehydrateen
dc.subjectcost-effectivnessen
dc.subjectextrafine-particle inhaled corticosteroiden
dc.subjectfixed-dose combination inhalersen
dc.subjectfluticasone propionate/salmeterol xinafoateen
dc.subjectlong-acting β2-agonisten
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleCost-Effectiveness of Asthma Step-Up Therapy as an Increased Dose of Extrafine-Particle Inhaled Corticosteroid or Add-On Long-Acting Beta2-Agonisten
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen, Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1007/s41030-016-0014-2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record